1.26

0.00% 0.00

After Hours: 1.25 -0.01 -0.79%

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $1.26, with a volume of 410.08K. It is up +0.00% in the last 24 hours and up +0.00% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Previous Close:

$1.26

Open:

$1.26

24h Volume:

410.08K

Relative Volume:

0.48

Market Cap:

$90.48M

Revenue:

Net Income/Loss:

$-292.19M

P/E Ratio:

-0.2775

EPS:

-4.54

Net Cash Flow:

$-208.41M

1W Performance:

+2.44%

1M Performance:

+0.00%

6M Performance:

-63.69%

1Y Performance:

-89.46%

1-Day Range:

$1.225

$1.265

1-Week Range:

$1.16

$1.325

52-Week Range:

$1.01

$13.00

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

166

Twitter

@ZentalisP

Next Earnings Date

2025-03-26

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	1.26	88.50M	0	-292.19M	-208.41M	-4.54
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

01:48 AM

Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World

01:48 AM

May 16, 2025

Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - Yahoo Finance

May 16, 2025

Zentalis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 16, 2025

May 15, 2025

Analyst Reiterates Neutral Rating for Zentalis Pharma (ZNTL) | ZNTL Stock News - GuruFocus

May 15, 2025

ZNTL: Oppenheimer Adjusts Price Target Amid Regulatory Developme - GuruFocus

May 15, 2025

Zentalis Pharma (ZNTL) Receives Buy Rating from HC Wainwright & Co. | ZNTL Stock News - GuruFocus

May 15, 2025

22,440 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Bought by Raymond James Financial Inc. - Defense World

May 15, 2025

May 14, 2025